Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Bristol-Myers

GlaxoSmithKline

Mylan

Novartis

Pfizer

Approvals were down slightly year over year.

FDA Approved 1,014 Generic Drugs in 2019

3 Reasons Why Teva Pharmaceutical Is Still A Good Buy

Teva: The Road To Perdition Has Turned Into A Path Towards Redemption

TEVA stock is about as far from a feel-good investment as you can get. But the underlying generics drug industry is still an important one, making shares a tough contrarian opportunity.

Opioids Made TEVA Stock Untouchable But Things Seem to be Changing

It seems to have been a long time since there were all that many positive statements about Teva Pharmaceutical Industries Ltd.

Why Teva’s Grand Turnaround Could Just Be Getting Started

Teva stock rose 9% after a positive earnings report. But after $3 billion in cost-cutting, investors may be looking for additional revenue.

Positive Earnings Look as If They’re Already Priced in to Teva Stock

Teva Pharmaceutical Industries Ltd (NYSE: TEVA) reported fourth-quarter sales and revenues that slightly exceeded estimates but issued a guarded outlook for 2020.

3 Analysts Dissect Teva's Q4 Results

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has cleared the decks, and the company is signaling full speed ahead.

Leaner, More Agile Teva Sees Brighter Days Ahead

Leaner, More Agile Teva Has Brighter Days Ahead

American Water Works

Canopy Growth

Deere & Company

iShares U.S. Healthcare ETF

iShares Dow Jones U.S. ETF

JPMorgan Chase & Co

NextEra Energy

Plug Power

SPDR S&P 500 ETF Trust

Tesla

United States Steel

SPDR S&P Homebuilders ETF

Exxon Mobil

Here's your complete guide on which stocks to buy, depending on who wins the 2020 U.S. Presidential Election.

15 Stocks to Buy Based On The 2020 U.S. Presidential Election

It increasingly appears that Teva stock is in the early stages of going from multi-year loser, to multi-year winner.
The post 3 Reasons Why Beaten-Up Teva Stock Could Have a Big 2020 appeared first on InvestorPlace.

3 Reasons Why Beaten-Up Teva Stock Could Have a Big 2020

Teva Pharmaceutical (TEVA) earnings match estimates but sales beat. Shares rise 9%.

Teva (TEVA) Q4 Earnings In Line, Stock Up as Sales Stabilize

The fourth-quarter report wasn't great, but there are signs that a turnaround is underway.

Teva Pharmaceutical Reports a Step Back in 2019

Bed Bath & Beyond

Express

 Luckin Coffee

OrganiGram Holdings Inc.

Pinterest

Stitch Fix

Stage Stores

Looking for a stock that will double or triple in 2020? These 10 lottery stocks have a realistic opportunity to do just that.

10 Strong Lottery Ticket Stocks That Could Soar in 2020

Teva Pharmaceutical Industries Limited (TEVA) CEO Kare Schultz on Q4 2019 Results - Earnings Call Transcript

Teva Pharmaceuticals (TEVA) earnings for the pharmaceutical company's fourth quarter of 2019 have TEVA stock taking off on Wednesday.
The post Teva Pharmaceuticals Earnings: TEVA Stock Takes 10% Jump on Q4 Beat appeared first on InvestorPlace.

Teva Pharmaceuticals Earnings: TEVA Stock Takes 10% Jump on Q4 Beat

The company's latest financial results are sparking investor optimism.

Why Teva Pharmaceutical Is Rallying 10% Today

Teva Pharmaceutical easily beat fourth-quarter expectations Wednesday, sending Teva stock rocketing to a nine-month high. Guidance was likely in line when accounting for a reporting change.

Why Drug Giant Teva Pharma Just Rocketed Into A Profit-Taking Zone

Teva Pharmaceutical (TEVA) matches earnings estimates but beats the same for sales. Shares rise in pre-market trading.

Teva (TEVA) Q4 Earnings In Line, Sales Beat, Stock Up

Teva Pharmaceutical Indus (NYSE: TEVA) reported fourth-quarter earnings of 64 cents per share, which beat the analyst consensus estimate of 61 cents by 4.92%.

Teva Reports Q4 Earnings Beat

Shares of Teva Pharmaceutical Industries Ltd. TEVA, -0.16% were down 1% in premarket trading on Wednesday after the Israeli drugmaker reported earnings of $110 million, or 10 cents per share, in the fourth quarter of 2019, after a loss of $2.9 billion, or $2.85 per share, in the same quarter in 2018.

Teva's stock falls on earnings; Copaxone sales tumble 26%

Teva Pharmaceutical edged past fourth-quarter earnings views, but the generic drug giant guided slightly lower on 2020 revenue. Shares fell early Wednesday.

Teva Earnings Narrowly Top, But Sales Guidance Light

Teva Pharmaceutical Indus (NYSE: TEVA) announces its next round of earnings this Wednesday, February 12.

Q4 Earnings Outlook For Teva

It appears more and more likely a case against opioid manufacturers and distributors will proceed to trial in New York state, keeping Bank of America bearish on the companies despite recent performance.

New York Opioid Case A Significant Risk For Pharma Stocks, Says Bearish BofA

Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.

News for Teva Pharmaceutical Stock (TEVA)